IL10 and neoplasm: As found in preclinical studies, PD‐1 blockade immunotherapy could stimulate tumor‐infiltrating DCs to secrete IL‐10, which subsequently upregulated PD‐1 in a STAT‐3‐dependent manner on DCs, hence creating a vicious circle of immune escape.124